Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  UnitedHealth Group    UNH

UNITEDHEALTH GROUP

(UNH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

UnitedHealth : Study Finds Seniors with COVID-19 Taking Hypertension Medication at Lower Risk of Hospitalization, Clinical Trial to Follow Immediately

share with twitter share with LinkedIn share with facebook
05/19/2020 | 10:01am EDT

A UnitedHealth Group and Yale School of Medicine study clears the way for clinical trials that could improve care and treatment for a vulnerable population

A study completed by UnitedHealth Group (NYSE: UNH) with the Yale School of Medicine found that older COVID-19 patients with hypertension taking angiotensin-converting enzyme (ACE) inhibitors had a lower risk of COVID-19 hospitalization. A pragmatic clinical trial will be a critical next step.

The study, which was recently submitted for peer-reviewed publication, analyzed retrospective data from about 10,000 patients testing positive for SARS-CoV-2 who were enrolled in Medicare Advantage or commercially insured plans, and had a prescription for one or more anti-hypertensive medications. The use of ACE inhibitors was associated with an almost 40% lower risk of COVID-19 hospitalization for Medicare Advantage patients. A younger, commercially insured group did not have the same result. Use of the medication was not found to reduce mortality risk in individuals once hospitalized with COVID-19.

“While not yet actionable, these findings provide an impetus to test whether this common, inexpensive class of drugs can mitigate the impact of the virus,” said Dr. Harlan Krumholz, the Harold H. Hines, Jr. professor of medicine at Yale and the director of the Yale New Haven Hospital Center for Outcomes Research.

The findings of this analysis clear a path for a pragmatic, large-scale clinical research trial to examine the potential role of ACE inhibitors in preventing the severe consequences of COVID-19. The large-scale research trial led by UnitedHealth Group and Yale School of Medicine will adopt an innovative, modern approach as one of the first virtual COVID-19 clinical trials to be launched at scale with a suite of digital tools.

“The results from this study offer critical new insights that can help accelerate clinical trials on ACEs to inform appropriate hypertension treatments for seniors during the COVID-19 pandemic,” said Dr. Deneen Vojta, executive vice president, Global Research & Development for UnitedHealth Group. “We are hopeful this information will help clinicians, health care researchers and industry leaders work together to validate these findings and possibly reduce the risk of hospitalization for COVID-19.”

To learn more about this forthcoming research trial and how to participate, visit www.unitedinresearch.com.

About UnitedHealth Group

UnitedHealth Group (NYSE: UNH) is a diversified health care company dedicated to helping people live healthier lives and helping to make the health system work better for everyone. UnitedHealth Group offers a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services. For more information, visit UnitedHealth Group at www.unitedhealthgroup.com or follow @UnitedHealthGrp on Twitter.


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
Latest news on UNITEDHEALTH GROUP
07/02UNITEDHEALTH GROUP : Announces Earnings Release Date
BU
06/25OPTUM : Wider Circle and Helping Hands Community Partner to Deliver Free, Fresh ..
BU
06/25UNITEDHEALTH : Urgent Care Centers Can Address Gaps in Access to Primary Care Ac..
BU
06/25HUMANA : Correction to DispatchHealth Series C Financing Article on June 23
DJ
06/24UNITEDHEALTHCARE : Dental Launches Teledentistry Option to Help Plan Participant..
BU
06/23The Big U.S. Stock Indexes Are Telling Different Stories -- Update
DJ
06/23UNITEDHEALTH : DispatchHealth Raises $135.8 Million in Series C Financing
DJ
06/19UNITEDHEALTH GROUP : Ex-dividend day for
FA
06/16U.S. health insurers may balk at paying for coronavirus antibody testing
RE
06/11UNITEDHEALTH : United Health Foundation Pledges $500,000 to Support Vulnerable A..
BU
More news
Financials (USD)
Sales 2020 258 B - -
Net income 2020 14 831 M - -
Net Debt 2020 21 218 M - -
P/E ratio 2020 19,2x
Yield 2020 1,54%
Capitalization 281 B 281 B -
EV / Sales 2019
EV / Sales 2020 1,17x
Nbr of Employees 325 000
Free-Float 99,3%
Chart UNITEDHEALTH GROUP
Duration : Period :
UnitedHealth Group Technical Analysis Chart | UNH | US91324P1021 | MarketScreener
Technical analysis trends UNITEDHEALTH GROUP
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 28
Average target price 330,14 $
Last Close Price 296,65 $
Spread / Highest target 29,4%
Spread / Average Target 11,3%
Spread / Lowest Target -4,60%
EPS Revisions
Managers
NameTitle
David Scott Wichmann Chief Executive Officer & Director
Andrew Philip Witty Group President
Stephen J. Hemsley Chairman
John Franklin Rex Chief Financial Officer & Executive Vice President
Richard J. Migliori Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
UNITEDHEALTH GROUP3.00%287 179
CIGNA CORPORATION-7.41%69 859
ANTHEM, INC.-10.94%67 819
HUMANA INC.8.17%52 414
CENTENE CORPORATION5.98%38 587
WELLCARE HEALTH PLANS5.97%17 611